A detailed history of State Street Corp transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 1,018,640 shares of ADGI stock, worth $3.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,018,640
Previous 982,736 3.65%
Holding current value
$3.37 Million
Previous $3.25 Million 3.66%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
N/A
35,904 Added 3.65%
1,018,640 $3.37 Million
Q2 2024

Aug 14, 2024

BUY
N/A
792,979 Added 417.89%
982,736 $3.25 Million
Q1 2024

May 15, 2024

BUY
N/A
14,500 Added 8.27%
189,757 $628,000
Q4 2023

Feb 14, 2024

SELL
N/A
-900 Reduced 0.51%
175,257 $580,000
Q2 2023

Aug 14, 2023

SELL
N/A
-831,711 Reduced 82.52%
176,157 $583,000
Q1 2023

May 15, 2023

BUY
N/A
886 Added 0.09%
1,007,868 $3.34 Million
Q4 2022

Feb 14, 2023

BUY
$3.08 - $4.05 $156,895 - $206,307
50,940 Added 5.33%
1,006,982 $3.33 Million
Q3 2022

Nov 15, 2022

BUY
$2.97 - $4.83 $62,043 - $100,898
20,890 Added 2.23%
956,042 $2.99 Million
Q2 2022

Aug 15, 2022

BUY
$2.54 - $4.52 $543,458 - $967,099
213,960 Added 29.67%
935,152 $3.07 Million
Q1 2022

May 16, 2022

SELL
$3.81 - $10.77 $3.44 Million - $9.73 Million
-903,088 Reduced 55.6%
721,192 $3.29 Million
Q4 2021

Feb 14, 2022

BUY
$6.35 - $47.04 $8.31 Million - $61.5 Million
1,308,202 Added 413.89%
1,624,280 $11.8 Million
Q3 2021

Nov 15, 2021

BUY
$20.88 - $56.08 $6.6 Million - $17.7 Million
316,078 New
316,078 $13.4 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.